-
公开(公告)号:US07576106B2
公开(公告)日:2009-08-18
申请号:US11580202
申请日:2006-10-11
申请人: Penglie Zhang , Andrew M. K. Pennell , Wei Chen , Kevin Lloyd Greenman , Edward J. Sullivan , Lianfa Li
发明人: Penglie Zhang , Andrew M. K. Pennell , Wei Chen , Kevin Lloyd Greenman , Edward J. Sullivan , Lianfa Li
IPC分类号: C07D401/06 , A61K31/454
CPC分类号: C07D401/06 , C07D211/42 , C07D211/52 , C07D211/56 , C07D211/60 , C07D211/64 , C07D401/14 , C07D413/14 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常是单环和双环化合物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07790726B2
公开(公告)日:2010-09-07
申请号:US11504215
申请日:2006-08-14
申请人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Lianfa Li , Edward J. Sullivan , Wei Chen , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Lianfa Li , Edward J. Sullivan , Wei Chen , Kevin Lloyd Greenman
IPC分类号: C07D263/58 , C07D413/06 , A61K31/496 , C07D401/06 , C07D498/04
CPC分类号: C07D413/06 , C07D231/56 , C07D233/36 , C07D235/26 , C07D263/22 , C07D263/58 , C07D265/18 , C07D295/185 , C07D401/06 , C07D413/04 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常是单环和双环化合物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07576218B2
公开(公告)日:2009-08-18
申请号:US11546938
申请日:2006-10-11
申请人: Penglie Zhang , Andrew M. K. Pennell , Wei Chen , Kevin Lloyd Greenman , Lianfa Li , Edward J. Sullivan , Valeri V. Martichonok
发明人: Penglie Zhang , Andrew M. K. Pennell , Wei Chen , Kevin Lloyd Greenman , Lianfa Li , Edward J. Sullivan , Valeri V. Martichonok
IPC分类号: C07D401/06 , A61K31/454
CPC分类号: C07D401/06 , C07D211/42 , C07D211/52 , C07D211/56 , C07D211/60 , C07D211/64 , C07D401/14 , C07D413/14 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常是单环和双环化合物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US07777035B2
公开(公告)日:2010-08-17
申请号:US11752201
申请日:2007-05-22
申请人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: C07D471/04
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Methods are provided for the synthesis of 1-[4-(substituted phenyl)-piperazin-1-yl ] -2- [3-(1H-imidazol-2-yl)-pyrazolo [3,4-b]pyridin-1-yl]-ethanone compounds via construction of the imidazole portion onto the corresponding aldehyde or nitrile compounds.
摘要翻译: 提供了合成1- [4-(取代的苯基) - 哌嗪-1-基] -2- [3-(1H-咪唑-2-基) - 吡唑并[3,4-b]吡啶-1 - 基] - 乙酮化合物通过将咪唑部分构建到相应的醛或腈化合物上。
-
公开(公告)号:US07786157B2
公开(公告)日:2010-08-31
申请号:US12048814
申请日:2008-03-14
IPC分类号: A01N43/50
CPC分类号: C07D233/32 , C07D261/06 , C07D401/04 , C07D413/06 , C07D413/14 , C07D471/04
摘要: The present invention provides compounds having formula (I): or pharmaceutically acceptable salts and N-oxides thereof, wherein the subscript m is an integer from 0-4; Ar is an optionally substituted aryl; B is an optionally substituted aryl; L1 is an optionally substituted linking group selected from the group consisting of C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and —CH2N(Ru)X5—; and L2 is a bond or C1-3 alkylene. The compounds act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity.
摘要翻译: 本发明提供具有式(I)的化合物或其药学上可接受的盐和N-氧化物,其中下标m是0-4的整数; Ar是任选取代的芳基; B是任选取代的芳基; L1是选自C1-4亚烷基,C1-4亚杂烷基,C2-4亚烯基和-CH2N(Ru)X5-的任选取代的连接基团; 并且L 2是键或C 1-3亚烷基。 该化合物作为CCR1受体的有效拮抗剂,具有体内抗炎活性。
-
公开(公告)号:US07524845B2
公开(公告)日:2009-04-28
申请号:US11474132
申请日:2006-06-22
申请人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu
发明人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu
IPC分类号: A61K31/5377 , A61K31/496 , C07D471/04 , C07D487/04
CPC分类号: C07D487/04 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US08383630B2
公开(公告)日:2013-02-26
申请号:US12829312
申请日:2010-07-01
申请人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu
发明人: Penglie Zhang , Andrew M. K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu
IPC分类号: A61K31/437 , A61P19/02
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Provided are methods for the treatment of rheumatoid arthritis using compounds of formula Ia and Ib: or a pharmaceutically acceptable salt, hydrate or N-oxide thereof.
摘要翻译: 提供了使用式Ia和Ib化合物或其药学上可接受的盐,水合物或N-氧化物治疗类风湿性关节炎的方法。
-
公开(公告)号:US20130338157A1
公开(公告)日:2013-12-19
申请号:US13774938
申请日:2013-02-22
申请人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: C07D471/04 , C07D487/04
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
-
公开(公告)号:US20110098308A1
公开(公告)日:2011-04-28
申请号:US12829312
申请日:2010-07-01
申请人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew M.K. Pennell , John J. Kim Wright , Wei Chen , Manmohan R. Leleti , Yandong Li , Lianfa Li , Yuan Xu , Mark M. Gleason , Yibin Zeng , Kevin Lloyd Greenman
IPC分类号: A61K31/497 , C07D471/04 , A61P19/02 , A61P25/00 , A61P17/00 , A61P1/00 , A61P37/08 , A61P25/16 , A61P25/28
CPC分类号: A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常为芳基哌嗪衍生物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
公开(公告)号:US20070066583A1
公开(公告)日:2007-03-22
申请号:US11504215
申请日:2006-08-14
申请人: Penglie Zhang , Andrew Pennell , John J. Wright , Lianfa Li , Edward Sullivan , Wei Chen , Kevin Lloyd Greenman
发明人: Penglie Zhang , Andrew Pennell , John J. Wright , Lianfa Li , Edward Sullivan , Wei Chen , Kevin Lloyd Greenman
IPC分类号: A61K31/55 , A61K31/506 , A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/454 , C07D417/02 , C07D413/02 , C07D403/02
CPC分类号: C07D413/06 , C07D231/56 , C07D233/36 , C07D235/26 , C07D263/22 , C07D263/58 , C07D265/18 , C07D295/185 , C07D401/06 , C07D413/04 , C07D471/04
摘要: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译: 提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。 化合物通常是单环和双环化合物,并且可用于药物组合物,用于治疗CCR1介导的疾病的方法,以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。
-
-
-
-
-
-
-
-
-